The Global Health Body Issues Warning Over Severe Scarcity of Obesity Injections

Less than 10% of individuals that would benefit from obesity jabs such as Wegovy can access them, warns the global health agency as it publishes its first guidance on the medications.

Considering more than one billion people worldwide currently classified as obese, it is calling for more widespread and fairer availability to this class of drugs.

Based on projections, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.

"The latest guidelines affirms that excess weight is a chronic disease that can be treated with holistic and continuous treatment," said its chief Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and distribution challenges are major barriers to universal availability to the jabs that can assist patients in reducing substantial body mass, says the organization.

Skinny Jab Shortage

Even in the present most favorable outlook, the production of GLP-1 therapies would only suffice for approximately 100 million people – fewer than 10% of the global need, according to the health organization.

The recommendation urges nations and manufacturers to increase access, by approaches such as patent sharing.

A patent on the active ingredient – the core component of the drug Wegovy – is set to lapse in multiple nations in 2026.

How Weight-Loss Jabs Operate

The injections mimick a body's own hormone to slow digestion, curb appetite and increase satiety so users eat less.

Individuals usually start to lose weight after several weeks of beginning the once-weekly jabs.

Evidence points to people may see weight return a year later of halting the medication, because their usual food cravings return.

Being carrying excess weight elevates your chance for experiencing medical conditions, such as diabetes, cardiovascular issues, brain attack, and some malignancies.

Excess weight impacts individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the WHO.